Cargando…
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120
BACKGROUND: Despite intensive risk-based treatment protocols, 15% of paediatric patients with B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL) experience relapse. There is urgent need of novel strategies to target poor prognosis subgroups, like PAX5 translocated. METHODS: We considered 289 c...
Autores principales: | Fazio, Grazia, Bresolin, Silvia, Silvestri, Daniela, Quadri, Manuel, Saitta, Claudia, Vendramini, Elena, Buldini, Barbara, Palmi, Chiara, Bardini, Michela, Grioni, Andrea, Rigamonti, Silvia, Galbiati, Marta, Mecca, Stefano, Savino, Angela Maria, Peloso, Alberto, Tu, Jia-Wey, Bhatia, Sanil, Borkhardt, Arndt, Micalizzi, Concetta, Lo Nigro, Luca, Locatelli, Franco, Conter, Valentino, Rizzari, Carmelo, Valsecchi, Maria Grazia, te Kronnie, Geertruij, Biondi, Andrea, Cazzaniga, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403348/ https://www.ncbi.nlm.nih.gov/pubmed/35985167 http://dx.doi.org/10.1016/j.ebiom.2022.104224 |
Ejemplares similares
-
Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
por: Xue, Cong, et al.
Publicado: (2016) -
Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012) -
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia
por: Palmi, Chiara, et al.
Publicado: (2023) -
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
por: Gori, Bruno, et al.
Publicado: (2011) -
BIBF1120 Protects against Diabetic Retinopathy through Neovascularization-Related Molecules and the MAPK Signaling Pathway
por: Cao, Xin, et al.
Publicado: (2023)